Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
$1.43
+0.7%
$0.99
$0.26
$16.50
$16.02M0.7872,594 shs27,097 shs
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
$5.67
$3.42
$12.72
$54.38M2.55132,982 shs36,800 shs
FONAR Co. stock logo
FONR
FONAR
$17.52
-0.5%
$19.78
$12.13
$24.05
$110.90M1.218,622 shs1,890 shs
IRIDEX Co. stock logo
IRIX
IRIDEX
$2.75
-2.1%
$2.83
$1.31
$3.65
$44.69M0.8232,571 shs798 shs
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
$0.31
-2.5%
$0.65
$0.22
$2.79
$3.47M1.13158,795 shs12,453 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
-16.96%+5.97%+119.37%+65.23%-89.44%
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
0.00%0.00%0.00%0.00%0.00%
FONAR Co. stock logo
FONR
FONAR
+7.97%+9.45%-9.88%-12.39%+8.24%
IRIDEX Co. stock logo
IRIX
IRIDEX
+0.18%-1.92%-8.63%+2.37%+23.03%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-1.22%+20.68%-13.95%-68.97%-82.07%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/AN/AN/AN/AN/AN/AN/AN/A
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/AN/AN/AN/AN/A
IRIDEX Co. stock logo
IRIX
IRIDEX
0.0033 of 5 stars
0.02.00.00.00.60.00.6
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
N/AN/AN/AN/A
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/AN/AN/AN/A
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/A
IRIDEX Co. stock logo
IRIX
IRIDEX
N/AN/A$2.00-27.27% Downside
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
$20K800.86N/AN/A($0.33) per share-4.33
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
$3.38M0.00N/AN/A$4.80 per share0.00
FONAR Co. stock logo
FONR
FONAR
$98.64M1.12$2.98 per share5.87$23.07 per share0.76
IRIDEX Co. stock logo
IRIX
IRIDEX
$51.87M0.86N/AN/A$0.59 per share4.66
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A$0.67 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
-$29.04M-$4.80N/AN/AN/A-8,129.09%-820.34%5/20/2024 (Estimated)
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
-$8.92MN/A0.00N/AN/AN/A-13.58%-13.02%N/A
FONAR Co. stock logo
FONR
FONAR
$9.38M$1.849.52N/A12.63%8.47%6.45%5/20/2024 (Estimated)
IRIDEX Co. stock logo
IRIX
IRIDEX
-$9.57M-$0.59N/AN/AN/A-18.45%-75.18%-25.99%5/9/2024 (Estimated)
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-$10.06M-$1.93N/AN/AN/A-197.36%-144.22%5/20/2024 (Estimated)

Latest FONR, IRIX, BSGM, EYES, and NDRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A-$0.17-$0.17-$0.17N/AN/A
3/26/2024Q4 2023
IRIDEX Co. stock logo
IRIX
IRIDEX
-$0.05-$0.18-$0.13-$0.18$14.90 million$12.46 million
2/14/2024Q2 2024
FONAR Co. stock logo
FONR
FONAR
N/A$0.54+$0.54$0.54N/A$25.39 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
N/AN/AN/AN/AN/A
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/AN/AN/AN/AN/A
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/AN/A
IRIDEX Co. stock logo
IRIX
IRIDEX
N/AN/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
N/A
0.12
0.12
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/A
22.15
22.15
FONAR Co. stock logo
FONR
FONAR
N/A
9.35
9.15
IRIDEX Co. stock logo
IRIX
IRIDEX
N/A
2.12
1.35
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A
6.26
3.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
7.16%
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
N/A
FONAR Co. stock logo
FONR
FONAR
50.64%
IRIDEX Co. stock logo
IRIX
IRIDEX
20.10%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
1.19%

Insider Ownership

CompanyInsider Ownership
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
9.30%
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
47.20%
FONAR Co. stock logo
FONR
FONAR
2.17%
IRIDEX Co. stock logo
IRIX
IRIDEX
6.20%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
4.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioSig Technologies, Inc. stock logo
BSGM
BioSig Technologies
411.20 million10.16 millionOptionable
Second Sight Medical Products, Inc. stock logo
EYES
Second Sight Medical Products
1513.14 million6.94 millionOptionable
FONAR Co. stock logo
FONR
FONAR
5616.33 million6.19 millionNot Optionable
IRIDEX Co. stock logo
IRIX
IRIDEX
11116.25 million15.25 millionOptionable
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
2111.04 million10.51 millionNot Optionable

FONR, IRIX, BSGM, EYES, and NDRA Headlines

SourceHeadline
ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024
finance.yahoo.com - May 7 at 8:51 AM
Life sciences firm picks Triangle over Boston, Philly for 170-job facilityLife sciences firm picks Triangle over Boston, Philly for 170-job facility
bizjournals.com - May 7 at 3:50 AM
Trends and Tips for Navigating Life Sciences M&A in 2024Trends and Tips for Navigating Life Sciences M&A in 2024
jdsupra.com - May 2 at 11:02 PM
ENDRA Life Sciences Inc.: ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International PatentsENDRA Life Sciences Inc.: ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
finanznachrichten.de - May 2 at 1:00 PM
Ingersoll Rand to bolster life sci presence with $2.3bn ILC Dover buyIngersoll Rand to bolster life sci presence with $2.3bn ILC Dover buy
bioprocessintl.com - May 2 at 1:00 PM
Lifes insiders: Decoding endosymbiosis with mathematicsLife's insiders: Decoding endosymbiosis with mathematics
msn.com - May 2 at 1:00 PM
ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International PatentsENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
businesswire.com - May 2 at 8:00 AM
San Diego’s life sciences sector struggles for financial securitySan Diego’s life sciences sector struggles for financial security
statnews.com - May 1 at 12:56 AM
Engineering professor, Kansas NSF leader named as final candidate for KU’s vice chancellor of researchEngineering professor, Kansas NSF leader named as final candidate for KU’s vice chancellor of research
www2.ljworld.com - April 29 at 3:37 PM
India’s Glenmark Life Sciences posts lower Q4 profit as Red Sea crisis hurts API businessIndia’s Glenmark Life Sciences posts lower Q4 profit as Red Sea crisis hurts API business
wsau.com - April 28 at 12:38 AM
Phase Sensitive Innovations to Open 12,000 SF Lab Facility in Newark, DelawarePhase Sensitive Innovations to Open 12,000 SF Lab Facility in Newark, Delaware
rebusinessonline.com - April 27 at 3:19 AM
Indias Glenmark Life Sciences posts lower Q4 profit as Red Sea crisis hurts API businessIndia's Glenmark Life Sciences posts lower Q4 profit as Red Sea crisis hurts API business
reuters.com - April 26 at 4:30 AM
Life sciences push brings new partner to OrrickLife sciences push brings new partner to Orrick
managingip.com - April 16 at 7:04 PM
IRA Capital Acquires 237,000 Square-Foot Life Science/R&D Campus in ColumbusIRA Capital Acquires 237,000 Square-Foot Life Science/R&D Campus in Columbus
markets.businessinsider.com - April 12 at 1:52 PM
Survey: Life Sciences Incubators Anticipate Continued GrowthSurvey: Life Sciences Incubators Anticipate Continued Growth
businessfacilities.com - April 10 at 2:00 PM
ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call TranscriptENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript
finance.yahoo.com - April 1 at 5:56 PM
Q4 2023 ENDRA Life Sciences Inc Earnings CallQ4 2023 ENDRA Life Sciences Inc Earnings Call
finance.yahoo.com - March 29 at 8:47 AM
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
businesswire.com - March 28 at 4:05 PM
Earnings Preview For ENDRA Life SciencesEarnings Preview For ENDRA Life Sciences
benzinga.com - March 27 at 2:48 PM
Ernest Pharmaceuticals Wins Levers Western Mass Health Technology ChallengeErnest Pharmaceuticals Wins Lever's Western Mass Health Technology Challenge
iberkshires.com - March 24 at 11:02 PM
ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024
finance.yahoo.com - March 21 at 10:37 AM
Report: 2024 U.S. Life Sciences Salary TrendsReport: 2024 U.S. Life Sciences Salary Trends
biospace.com - March 19 at 12:51 AM
Life Science Analytics Market Surges to US$ 68.6 Billion by 2032 with 10.7% CAGRLife Science Analytics Market Surges to US$ 68.6 Billion by 2032 with 10.7% CAGR
fmiblog.com - March 18 at 2:53 AM
The Boston area built a ton of lab space. Now many of those buildings are opening emptyThe Boston area built a ton of lab space. Now many of those buildings are opening empty
statnews.com - March 16 at 7:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BioSig Technologies logo

BioSig Technologies

NASDAQ:BSGM
BioSig Technologies, Inc., together with its subsidiaries, a medical device company, commercializes advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias. The company offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for catheter ablation procedures for arrhythmias. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Second Sight Medical Products logo

Second Sight Medical Products

NASDAQ:EYES
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
FONAR logo

FONAR

NASDAQ:FONR
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company also offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters, and development and implementation of practice growth and marketing strategies. It owns and operates diagnostic imaging facilities in Florida; and manages MRI scanning facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1970 and is based in Melville, New York.
IRIDEX logo

IRIDEX

NASDAQ:IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
ENDRA Life Sciences logo

ENDRA Life Sciences

NASDAQ:NDRA
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.